Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (71-80 of 395) with videos related to

Pageof 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2014
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designsJuliane M Jürgensmeier, Joseph P Eder, Roy S Herbst
Nature Reviews. Clinical Oncology|June 25, 2021
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLCMichael J Grant, Roy S Herbst, Sarah B Goldberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2023
Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private PartnershipsRoy S Herbst, Charles D Blanke, Ellen V Sigal
Expert Opinion on Biological Therapy|December 1, 2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancerR S Herbst, E S Kim, P M Harari
Hematology/Oncology Clinics of North America|June 1, 1997
Chemotherapy for advanced non-small cell lung cancerR S Herbst, N H Dang, A T Skarin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancerRoy S Herbst, Yun Oh, Asavari Wagle, et al.
Clinical Lung Cancer|March 18, 2009
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapyRoy S Herbst, Thomas J Lynch, Alan B Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2014
"Companion diagnostics": has their time come and gone?Fred R Hirsch, Paul A Bunn, Roy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerAlan B Sandler, David H Johnson, Roy S Herbst
Nature Reviews. Clinical Oncology|December 24, 2009
Surgery: Future directions in multimodality therapy for NSCLCAnne S Tsao, Jack A Roth, Roy S Herbst
Pageof 40

Showing results (71-80 of 395) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2014
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designsJuliane M Jürgensmeier, Joseph P Eder, Roy S Herbst
Nature Reviews. Clinical Oncology|June 25, 2021
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLCMichael J Grant, Roy S Herbst, Sarah B Goldberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2023
Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private PartnershipsRoy S Herbst, Charles D Blanke, Ellen V Sigal
Expert Opinion on Biological Therapy|December 1, 2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancerR S Herbst, E S Kim, P M Harari
Hematology/Oncology Clinics of North America|June 1, 1997
Chemotherapy for advanced non-small cell lung cancerR S Herbst, N H Dang, A T Skarin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancerRoy S Herbst, Yun Oh, Asavari Wagle, et al.
Clinical Lung Cancer|March 18, 2009
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapyRoy S Herbst, Thomas J Lynch, Alan B Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2014
"Companion diagnostics": has their time come and gone?Fred R Hirsch, Paul A Bunn, Roy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerAlan B Sandler, David H Johnson, Roy S Herbst
Nature Reviews. Clinical Oncology|December 24, 2009
Surgery: Future directions in multimodality therapy for NSCLCAnne S Tsao, Jack A Roth, Roy S Herbst
Pageof 40